Navigation Links
Research Reports Initiation on Biotech Stocks -- Epizyme, Sierra Oncology, Five Prime Therapeutics, and AveXis
Date:4/11/2017

NEW YORK, April 11, 2017 /PRNewswire/ --

On Monday, April 10, 2017, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 5,880.93, up 0.05%; the Dow Jones Industrial Average edged 0.01% higher, to finish at 20,658.02; and the S&P 500 closed at 2,357.16, up 0.07%. This Tuesday morning, Stock-Callers.com looks at the performance of these four Biotechnology stocks: Epizyme Inc. (NASDAQ: EPZM), Sierra Oncology Inc. (NASDAQ: SRRA), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and AveXis Inc. (NASDAQ: AVXS). You can access our complimentary research reports on these stocks now at:

http://stock-callers.com/registration

Epizyme  

Cambridge, Massachusetts headquartered Epizyme Inc.'s stock finished Monday's session 0.34% lower at $14.60, with a total volume of 168,787 shares traded. Over the last three months and the previous one year, Epizyme's shares have gained 22.18% and 20.16%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 2.16% and 32.42%, respectively. Shares of Epizyme, which discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the US, have a Relative Strength Index (RSI) of 37.84. Visit us today and download your complete report on EPZM for free at:

http://stock-callers.com/registration/?symbol=EPZM


Sierra Oncology 

Vancouver, Canada headquartered Sierra Oncology Inc.'s stock closed the day flat at $1.43. The stock recorded a trading volume of 208,333 shares. Sierra Oncology's shares are trading 1.64% and 13.65% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which engages in developing DNA Damage Response therapeutics for the treatment of patients with cancer, have an RSI of 44.91. The complimentary research report on SRRA can be accessed at:


http://stock-callers.com/registration/?symbol=SRRA


Five Prime Therapeutics  

On Monday, shares in San Francisco, California headquartered Five Prime Therapeutics Inc. ended the session 2.92% higher at $33.84, with a total volume of 541,168 shares traded. Five Prime Therapeutics' shares are trading 19.13% below its 50-day moving average and 28.83% below its 200-day moving average. Moreover, shares of the Company, which focuses on the discovery and development of immuno-oncology protein therapeutics in the US, have an RSI of 31.91. Register for free on Stock-Callers.com and download the PDF research report on FPRX at:

http://stock-callers.com/registration/?symbol=FPRX


AveXis  

On Monday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 325,113 shares. The stock ended the day 1.54% lower at $68.40. AveXis' stock has surged 22.76% in the last three months and 193.81% in the previous one year. The Company's shares are trading above its 50-day and 200-day moving averages by 3.21% and 33.58%, respectively. Furthermore, shares of AveXis, which engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases, have an RSI of 42.49.

On March 30th, 2017, research firm UBS initiated a 'Buy' rating on the Company's stock, with a target price of $95 per share. Get free access to your research report on AVXS at:

http://stock-callers.com/registration/?symbol=AVXS

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



'/>"/>
SOURCE Chelmsford Park SA
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. China Proton Therapy Market & Forecast, 2021: Patients Treated at Proton Therapy Facility, Reimbursement Policy 2009-2021 - Research and Markets
2. Russia Proton Therapy Market & Forecast Report 2017: Untapped Market of Proton Therapy in Russia Would Be More Than US$ 3 Billion During Forecast Period - Research and Markets
3. Global Pharmaceutical Contract Packaging Market to Grow at a CAGR of 14.5% by 2021 - High Demand for Pharmaceutical Contract Packaging in Emerging Economies - Research and Markets
4. Research and Markets - Global Respiratory Diagnostic and Monitoring Device Market, 2022: Key Players are General Electric, Masimo, Hamilton Medical, Koninklijke Philips & Medtronic
5. Cardiovascular Disorders Drug Development Pipeline Review 2017: 1,200 Pipeline Products within the CVD Therapy Area - Research and Markets
6. Medical Device Market Research Bundle Report 2017: Collection of Reports Exploring the Key Dynamics of the Market - Research and Markets
7. Antibacterial Therapies Drug Development Pipeline Review 2017: 1400 Products in Active Development - Which Companies are the Most Active? - Research and Markets
8. Global Advanced Remote Patient Monitoring Systems Markets 2012-2021 - Research and Markets
9. Global Emerging Cancer Diagnostics Market Analysis & Forecast 2017-2023: Market Is Expected To Grow At A CAGR Of 13.45% and Reach $6.34 Billion - Research and Markets
10. Cell-Free DNA (cfDNA) Markets, 2021: Consumables, Systems/Hardware, Services - Research and Markets
11. Two Day Seminar: Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices (Cambridge, United States - November 9-10, 2017) - Research and Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):